Recruiting Clinical Trials

Displaying 201 - 210 of 245 result(s)
Study Title Condition Phase Location
Impact of Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib) on Patients Quality of Life (QoL) and Clinical Outcomes in Portuguese Real World Setting Malignant Melanoma Not Given
  • Country: 
    Portugal
Russian Registry of Patients With Neovascular Age-Related Macular Degeneration (nAMD) Neovascular Age-Related Macular Degeneration Not Given
  • Country: 
    Russian Federation
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for Neovascular Age-related Macular Degeneration (nAMD) in Portugal Neovascular Age-related Macular Degeneration (nAMD) Not Given
  • Country: 
    Portugal
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent (Siponimod): An OTIS Observational Pregnancy Surveillance Study Multiple Sclerosis Not Given
  • Country: 
    United States
A Descriptive Study of PIK3CA Mutations and Outcomes With Alpelisib in Patients With HR-positive and HER2-negative Advanced Breast Cancer (ABC)/ Metastatic Breast Cancer (MBC) in India Breast Cancer Not Given
  • Country: 
    India
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer BRAF V600 Colorectal Cancer Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Belgium
  • Country: 
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors Solid Tumors Phase 1
  • Country: 
    United States
  • Country: 
    Canada
  • Country: 
    Hong Kong
  • Country: 
A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia Phase 1
  • Country: 
    Finland
  • Country: 
    Germany
  • Country: 
    Israel
  • Country: 
Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N) Non-small Cell Lung Cancer Phase 2
  • Country: 
    United States
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT) Sickle Cell Disease Not Given
  • Country: 
    Bahrain
  • Country: 
    India
  • Country: 
    Kuwait
  • Country: